Nestle will pay US$2 billion to buy the remaining stake in Aimmune Therapeutics Inc, gaining full ownership of the first US-approved peanut allergy treatment.
WATCH MORE: https://thestartv.com/c/news
SUBSCRIBE: https://cutt.ly/TheStar
LIKE: https://fb.com/TheStarOnline
